猴痘
公共卫生
医学
业务
心理干预
全球卫生
环境卫生
医疗急救
病毒学
生物
病理
护理部
重组DNA
生物化学
基因
牛痘
作者
Jim F. Huggett,David French,Denise M. O’Sullivan,Jacob Moran‐Gilad,Alimuddin Zumla
出处
期刊:Eurosurveillance
[European Centre for Disease Control and Prevention (ECDC)]
日期:2022-08-11
卷期号:27 (32)
被引量:40
标识
DOI:10.2807/1560-7917.es.2022.27.32.2200497
摘要
Monkeypox was declared a public health emergency of international concern by the World Health Organization (WHO) on 23 July 2022. Between 1 January and 23 July 2022, 16,016 laboratory confirmed cases of monkeypox and five deaths were reported to WHO from 75 countries on all continents. Public health authorities are proactively identifying cases and tracing their contacts to contain its spread. As with COVID-19, PCR is the only method capable of being deployed at sufficient speed to provide timely feedback on any public health interventions. However, at this point, there is little information on how those PCR assays are being standardised between laboratories. A likely reason is that testing is still limited on a global scale and that detection, not quantification, of monkeypox virus DNA is the main clinical requirement. Yet we should not be complacent about PCR performance. As testing requirements increase rapidly and specimens become more diverse, it would be prudent to ensure PCR accuracy from the outset to support harmonisation and ease regulatory conformance. Lessons from COVID-19 should aid implementation with appropriate material, documentary and methodological standards offering dynamic mechanisms to ensure testing that most accurately guides public health decisions.
科研通智能强力驱动
Strongly Powered by AbleSci AI